At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 240 enrolled
Drug / intervention
10 mg of Ketorolac +2 moredrug
Likely dose
10 mg of Ketorolacfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department"
In Brief
A Phase 4 clinical trial evaluating 10 mg of Ketorolac, 15 mg of Ketorolac, and 1 other intervention for Pain. Completed, enrolled 240 participants across 1 site.
Detailed Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedMar 5, 2014
Enrollment StartMar 1, 2014
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago
Interventions
10 mg of Ketorolacdrug
Patients will receive 10 mg of Ketorolac for pain control.
15 mg of Ketorolacdrug
Patients will receive 15mg of Ketorolac for pain control.
30 mg of Ketorolacdrug
Patients will receive 30mg of Ketorolac for pain control.